Partnership will increase hypoactive sexual
desire disorder (HSDD) awareness and expand access to Vyleesi via
UpScriptHealth's Women's Health Platform
CRANBURY, N.J., Aug. 7, 2023
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin
receptor system, today announced that it has entered a strategic
partnership with UpScriptHealth, a leading direct-to-consumer
telemedicine company providing telemedicine services to
pharmaceutical and medical technology companies. Under terms of the
agreement, UpScriptHealth will make Vyleesi available to the
hundreds of thousands of patients in its proprietary Women's
Telehealth Platform. Vyleesi is the first and only as-needed
treatment approved by the U.S. Food and Drug Administration (FDA)
for premenopausal women with acquired, generalized hypoactive
sexual desire disorder (HSDD).
"We are excited to partner with UpScriptHealth, a pioneer in
telehealth," stated Carl Spana,
Ph.D., President and Chief Executive Officer of Palatin. "This
partnership fortifies our existing telehealth programs and provides
a platform to create greater awareness of HSDD and access to
Vyleesi through UpScriptHealth's patient base of hundreds of
thousands of women."
"UpScriptHealth's Women's Telehealth Platform was launched in
2015 to provide women with a convenient way to consult healthcare
providers and obtain therapies to improve the quality of their
lives," stated Peter Ax, Founder and
Chief Executive Officer of UpScriptHealth. "The addition of Vyleesi
furthers our female health strategy and provides our patient base
with education surrounding HSDD as a significant and common
condition, and importantly, access to a meaningful treatment
option."
About Vyleesi® (bremelanotide injection) for
Hypoactive Sexual Desire Disorder (HSDD)
Vyleesi is the first and only as-needed treatment approved by
the FDA for premenopausal women with acquired, generalized
HSDD.
Palatin is actively seeking Vyleesi collaborations for
the United States and for
territories outside the currently licensed territories of
China and South Korea. Vyleesi is licensed to Fosun
Pharma in China and Kwangdong
Pharmaceuticals in South
Korea.
Patients and healthcare providers can learn more about HSDD and
Vyleesi at www.vyleesi.com and www.vyleesipro.com.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor systems, with targeted, receptor-specific
product candidates for the treatment of diseases with significant
unmet medical need and commercial potential. Palatin's strategy is
to develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.Palatin.com and follow Palatin on Twitter at
@PalatinTech.
About UpScriptHealth
UpScriptHealth™ is the leading comprehensive, direct-to-consumer
telehealth and virtual prescribing platform that has been
innovating the way customers receive care and obtain medications
for more than two decades. UpScriptHealth is committed to improving
the lives of consumers by providing immediate and long-term
convenient access to medical therapies. UpScriptHealth's philosophy
of providing extraordinary care is strengthened through their core
values of transparency, integrity and the relentless pursuit of
excellence. To learn more about UpScriptHealth, visit
www.UpScriptHealth.com and www.PrjktRuby.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin, such as
statements about Vyleesi market initiatives and anticipated
benefits, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating events that
occur after the date of this press release.
Palatin Technologies® and Vyleesi® are
registered trademarks of Palatin Technologies, Inc.
UpScriptHealth™ is a trademark of UpScript IP Holdings, LLC.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-announces-direct-to-consumer-telehealth-partnership-with-upscripthealth-for-vyleesi-301893398.html
SOURCE Palatin Technologies, Inc.